NL-OMON50198已完成4 期
Pharmacokinetics of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children (VALID II). - VALID-2
Afdeling Apotheek0 个研究点目标入组 7 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •1. Subject is in the age of 1-12 years.
- •2. Subject receives (val)acyclovir prophylaxis and is planned to receive
- •valacyclovir oral solution.
- •3. Subject is managed with a central venous catheter (CVC/Port-a-Cath).
- •4. Subject*s parents have signed the Informed Consent Form prior to screening
- •evaluations.
排除标准
- •1. Severe anemia (Hb < 5.0 mmol/L).
- •2. Full dose has not been taken.
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetic testing of a new paediatric formulation of valacyclovir.Herpes virus infections, especially Herpes Simplex and Varicella Zoster.MedDRA version: 20.0Level: PTClassification code 10019973Term: Herpes virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001451-30-NLRadboud university medical center16
已完成
不适用
Acceptability study of a new paediatric formulation of Orphacol® (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-?5-C27- steroid oxidoreductase deficiency or ?4-3-Oxosteroid-5ß-reductase deficiency.K76.8Other specified diseases of liverDRKS00013645aboratoires CTRS4
招募中
不适用
Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children - VALID 0chickenpoxherpes10047438NL-OMON43617niversitair Medisch Centrum60
进行中（未招募）
1 期
Palatability testing of a new paediatric formulation of valacyclovirHerpes virus infections, especially Herpes Simplex, Varicella Zoster and CytomegalovirusMedDRA version: 14.1Level: PTClassification code 10019973Term: Herpes virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000577-22-NLRadboud University Nijmegen Medical Centre64
已完成
1 期
A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) FormulationsHealthyNCT04338711Pfizer23